Patents Examined by Christine J. Saoud
  • FN14-binding proteins and uses thereof
    Patent number: 10584175
    Abstract: The present invention provides an isolated or recombinant Fn14-binding protein comprising an antigen binding do main, wherein the antigen binding domain binds specifically to Fn14 or a cell expressing Fn14.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: March 10, 2020
    Assignee: La Trobe University
    Inventor: Joanne Casey
  • Method for evaluating and selecting agent for suppressing odors of sulfide compounds
    Patent number: 10585087
    Abstract: The present invention identifies substances which suppress odors of sulfide compounds. Provided is a method for evaluating and/or selecting an agent for suppressing odors of sulfide compounds, the method comprising: adding a test substance and a sulfide compound to at least one olfactory receptor polypeptide selected from the group consisting of OR4S2 and polypeptides having an amino acid sequence identity of at least 80% to OR4S2; and measuring the response of the olfactory receptor polypeptide to the sulfide compound.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: March 10, 2020
    Assignee: KAO CORPORATION
    Inventors: Keiichi Yoshikawa, Naoko Saito
  • Pharmaceutical composition of an anti-VEGF antibody
    Patent number: 10568951
    Abstract: The present invention relates to liquid pharmaceutical formulations for intravitreal injection of an anti-VEGF antibody which does not contain saccharides for use in the treatment of age-related macular degeneration.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: February 25, 2020
    Assignee: FORMYCON AG
    Inventor: Rainer Sigl
  • Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
    Patent number: 10561709
    Abstract: Disclosed are the use of neuregulin proteins in preparing a medicine for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, and a method for using the medicine. Also provided in the present invention is a method for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, comprising using the medication containing the neuregulin proteins in a special population having the disease or being at risk of having the disease.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: February 18, 2020
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou
  • Method of modulating sex hormone levels using a sex hormone secretion modulator
    Patent number: 10561703
    Abstract: Provided are a hormone secretion modulator including a peptide derived from telomerase, more particularly, a peptide including an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having a sequence identity of at least 80% with SEQ ID NO: 1, or a fragment thereof, a pharmaceutical composition including the hormone secretion modulator, and a use of the pharmaceutical composition for treatment, alleviation, or prevention of diseases caused by excessive or deficient levels hormones.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: February 18, 2020
    Assignee: GemVaX & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Anti human Gas6 monoclonal antibody
    Patent number: 10561727
    Abstract: The present invention relates to an antibody specifically binding to human growth arrest specific 6 (hGas6). Specifically, the present invention relates to a monoclonal antibody or an antibody fragment thereof which binds to at least one of amino acid residues at positions 314, 315, and 316 of human Gas6, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment, a transformed cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment, a reagent for detection or assay of Gas6, comprising the antibody or the antibody fragment, a therapeutic agent or a diagnostic agent for a Gas6-related disease, comprising the antibody or the antibody fragment as an active ingredient, and use of the antibody or the antibody fragment for the production of a therapeutic agent or a diagnostic agent for a Gas6-related disease.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: February 18, 2020
    Assignee: Kyowa Kirin Co., Ltd.
    Inventors: Yuko Ube, Tsuyoshi Yamada, Yuji Yamazaki, Kaname Kimura, Akiko Hariguchi, Shinya Ogawa
  • Antibody which binds Lrg1 and methods of use
    Patent number: 10556007
    Abstract: The invention provides an antibody or fragment thereof that specifically binds to human Lrg1.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: February 11, 2020
    Assignee: UCL Business LTD
    Inventors: Vineeta Tripathi, Rose Sheridan, John Greenwood, Stephen Moss
  • Methods of treatment of keloid using an anti-VEGF agent
    Patent number: 10556008
    Abstract: Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: February 11, 2020
    Inventor: Randal Tanh Hoang Pham
  • FGF-23 epitope peptide for improving resistance to breakage and eggshell strength
    Patent number: 10544197
    Abstract: Described herein are FGF-23 epitope peptides, methods of producing antibodies in laying hens by injecting the peptides, and methods of improving resistance to eggshell breakage and/or increasing eggshell strength by administering an FGF-23 epitope peptide to a laying hen.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: January 28, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Mark Eric Cook, Zhouzheng Ren, Alexis Jo Piepenburg, Daniel Butz
  • Combination therapy utilizing P2X7 peptides
    Patent number: 10543262
    Abstract: The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimising the progression of cancer in said individuals.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: January 28, 2020
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • P2X7 receptor antagonists and agonists
    Patent number: 10544216
    Abstract: The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: January 28, 2020
    Assignees: Ablynx N.V., University Medical Center Hamburg-Eppendorf
    Inventors: Welbeck Owusu Danquah, Friedrich Nolte, Catelijne Stortelers, Toon Laeremans
  • Methods of treating wounds in a diabetic subject
    Patent number: 10543270
    Abstract: The present disclosure provides a method of treating wound healing in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signalling.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: January 28, 2020
    Assignees: CSL LIMITED, B-CREATIVE SWEDEN AB
    Inventors: Ulf Eriksson, Annelie Falkevall, Annika Mehlem
  • Monomeric CXCL121 peptide and methods of treating autoimmune diseases
    Patent number: 10537613
    Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 21, 2020
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson
  • Soluble IGF receptor Fc fusion proteins and uses thereof
    Patent number: 10538575
    Abstract: There are described herein novel soluble IGF receptor Fc fusion proteins and compositions and methods of use thereof for treating angiogenesis associated disorders and malignant disease, such as cancer and metastasis, wherein the fusion proteins bind specifically to IGF-1 or IGF-2.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: January 21, 2020
    Inventors: Pnina Brodt, Bernard Massie, Traian Sulea
  • Methods for inducing differentiation or conversion of white adipocytes and/or preadipocytes to brown adipocites using FGF8
    Patent number: 10532083
    Abstract: The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis. Also provided by the present invention are pharmaceutical compositions comprising said polypeptides and polynucleotides for use in treating diseases or disorders of energy homeostasis. Said polypeptides, polynucleotides and pharmaceutical compositions may be administered locally, in particular locally into the visceral adipose tissue. Another aspect of the invention relates to a cosmetic product and the use of said cosmetic product for reducing body weight, in particular for reducing abdominal adipose tissue.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: January 14, 2020
    Assignee: Technische Universität München
    Inventors: Sören Westphal, Tobias Fromme, Martin Klingenspor
  • Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
    Patent number: 10532096
    Abstract: The present invention provides pharmaceutical compositions comprising a VEGF antagonist and an anti-CTLA-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: January 14, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Ella Ioffe, Israel Lowy, Gavin Thurston, Elena Burova
  • Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
    Patent number: 10525101
    Abstract: Recombinant polypeptides, pharmaceutical compositions comprising recombinant polypeptides, and methods of treating autoimmune and/or inflammatory diseases using the pharmaceutical compositions are disclosed. The polypeptides are based upon the trimerization and/or MIF binding domains of CD74.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: January 7, 2020
    Assignees: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Arthur A. Vandenbark, Gil Benedek, Roberto Meza-Romero
  • Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
    Patent number: 10525104
    Abstract: The present invention provides methods for treating metastatic cancer comprising identifying subjects who will respond favorably to anti-VEGF therapy. According to certain aspects of the invention, subjects are identified based on their expression level of one or more predictive biomarkers. Favorable response to anti-VEGF therapy is indicated by high expression levels of certain biomarkers or by low expression levels of certain biomarkers. An exemplary predictive biomarker is VEGF-A. Also disclosed herein are prognostic biomarkers useful for identifying cancer-bearing subjects who are expected to have better relative survival outcomes.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: January 7, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Tasha Nicholle Sims, Bo Gao, Israel Lowy
  • Pharmaceutical compositions comprising FGF19 variants
    Patent number: 10517929
    Abstract: Provided herein are pharmaceutical compositions, formulations and dosage forms comprising variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). Methods of using the pharmaceutical compositions, formulations and dosage forms are also provided herein.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: December 31, 2019
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Darrin Anthony Lindhout, Charles V. Olson
  • Anti-FGFR1c antibody-FGF21 fusion proteins
    Patent number: 10519240
    Abstract: The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ?Klotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided are methods of treating various metabolic disorders by administering the FGF21R agonists and/or anti-FGF21 antibodies to a subject in need thereof.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: December 31, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: George D. Yancopoulos, Andrew J. Murphy, Jesper Gromada, David R. Buckler, Kihwa Kang